EA201270617A2 - Способы лечения или предотвращения тромбоза стента - Google Patents

Способы лечения или предотвращения тромбоза стента

Info

Publication number
EA201270617A2
EA201270617A2 EA201270617A EA201270617A EA201270617A2 EA 201270617 A2 EA201270617 A2 EA 201270617A2 EA 201270617 A EA201270617 A EA 201270617A EA 201270617 A EA201270617 A EA 201270617A EA 201270617 A2 EA201270617 A2 EA 201270617A2
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
bivalirudin
kangrelor
useful
necessary
Prior art date
Application number
EA201270617A
Other languages
English (en)
Other versions
EA028885B1 (ru
Inventor
Клив Артур Аркулус-Минвелл
Симона Скержанец
Original Assignee
Зе Медисинс Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43974647&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201270617(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Зе Медисинс Компани filed Critical Зе Медисинс Компани
Publication of EA201270617A2 publication Critical patent/EA201270617A2/ru
Publication of EA028885B1 publication Critical patent/EA028885B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A61K38/58—Protease inhibitors from animals; from humans from leeches, e.g. hirudin, eglin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)

Abstract

Настоящее изобретение относится к способам лечения или предотвращения тромбоза стента с использованием фармацевтических композиций, содержащих кангрелор и при необходимости бивалирудин; способам уменьшения смертности субъекта, подвергшегося имплантации стента с использованием фармацевтических композиций, содержащих кангрелор и при необходимости бивалирудин; медикаментам, содержащим кангрелор и при необходимости бивалирудин, полезным для лечения или предотвращения тромбоза стента или полезным для уменьшения смертности субъекта, подвергшегося имплантации стента; фармацевтическим композициям, содержащим кангрелор и бивалирудин; и способам приготовления лекарства, содержащего кангрелор и при необходимости бивалирудин, полезного для лечения или предотвращения тромбоза стента или полезного для уменьшения смертности субъекта, подвергшегося имплантации стента.
EA201270617A 2009-11-11 2010-11-10 Способы лечения или предотвращения тромбоза стента и инфаркта миокарда (варианты) EA028885B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26036109P 2009-11-11 2009-11-11
PCT/US2010/056225 WO2011060066A2 (en) 2009-11-11 2010-11-10 Methods of treating or preventing stent thrombosis

Publications (2)

Publication Number Publication Date
EA201270617A2 true EA201270617A2 (ru) 2013-01-30
EA028885B1 EA028885B1 (ru) 2018-01-31

Family

ID=43974647

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201270617A EA028885B1 (ru) 2009-11-11 2010-11-10 Способы лечения или предотвращения тромбоза стента и инфаркта миокарда (варианты)

Country Status (13)

Country Link
US (3) US9925265B2 (ru)
EP (1) EP2498731B1 (ru)
AU (1) AU2010319612B2 (ru)
BR (1) BR112012011298B1 (ru)
CA (1) CA2778880C (ru)
DK (1) DK2498731T3 (ru)
EA (1) EA028885B1 (ru)
ES (1) ES2773040T3 (ru)
HR (1) HRP20200445T1 (ru)
PL (1) PL2498731T3 (ru)
PT (1) PT2498731T (ru)
SI (1) SI2498731T1 (ru)
WO (1) WO2011060066A2 (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2733409C2 (ru) * 2015-01-14 2020-10-01 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Фармацевтические составы, включающие кангрелор высокой чистоты, и способы их получения и применения

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9427448B2 (en) 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
US20130303477A1 (en) 2008-05-13 2013-11-14 The Medicines Company Maintenance of Platelet Inhibition During Antiplatelet Therapy
US8759316B2 (en) 2008-05-13 2014-06-24 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US8680052B1 (en) 2013-03-09 2014-03-25 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
WO2009140092A1 (en) 2008-05-13 2009-11-19 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US20120141468A1 (en) 2008-05-13 2012-06-07 Lisa Ruderman Chen Maintenance of platelet inhibition during antiplatelet therapy
US10376532B2 (en) * 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
CA2778880C (en) * 2009-11-11 2018-02-13 The Medicines Company Methods of treating or preventing stent thrombosis
EP2672975B1 (en) * 2011-02-09 2016-04-20 The Medicines Company Methods for treating pulmonary hypertension
MX359768B (es) 2012-10-26 2018-10-10 Chiesi Farm Spa Métodos para controlar la presión arterial y para reducir la disnea durante una insuficiencia cardiaca.
ES2904256T3 (es) * 2013-03-09 2022-04-04 Chiesi Farm Spa Métodos para tratar, reducir la incidencia de y/o prevenir eventos isquémicos
WO2014142780A1 (en) * 2013-03-09 2014-09-18 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
WO2014209389A1 (en) * 2013-06-26 2014-12-31 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
WO2015054542A1 (en) * 2013-10-09 2015-04-16 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
BR112019022676A2 (pt) 2017-06-23 2020-05-19 Chiesi Farm Spa método de prevenção de trombose de derivação da artéria sistêmica-para-pulmonar

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2530247B1 (fr) 1982-07-13 1986-05-16 Sanofi Sa Nouveaux derives de la thieno (3, 2-c) pyridine, leur procede de preparation et leur application therapeutique
US5196404B1 (en) 1989-08-18 1996-09-10 Biogen Inc Inhibitors of thrombin
FI101150B (fi) 1991-09-09 1998-04-30 Sankyo Co Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi
CA2155673C (en) 1993-02-10 2004-08-17 Anthony Howard Ingall N-alkyl-2-substituted atp analogues
SE9604795D0 (sv) 1996-12-20 1996-12-20 Astra Pharma Prod New pharmaceutical formulation
SE9702680D0 (sv) 1997-07-11 1997-07-11 Astra Pharma Prod New formulation
SE9904377D0 (sv) 1999-12-01 1999-12-01 Astra Pharma Prod Pharmaceutical combinations
DE60134508D1 (de) 2000-07-06 2008-07-31 Daiichi Sankyo Co Ltd Säure-Additionssalze von Hydropyridinderivaten
US7132408B2 (en) 2000-08-21 2006-11-07 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US20020123791A1 (en) * 2000-12-28 2002-09-05 Harrison William J. Stent design with increased vessel coverage
US6861424B2 (en) 2001-06-06 2005-03-01 Schering Aktiengesellschaft Platelet adenosine diphosphate receptor antagonists
US7758630B2 (en) * 2003-04-14 2010-07-20 Tryton Medical, Inc. Helical ostium support for treating vascular bifurcations
US7749981B2 (en) 2003-10-21 2010-07-06 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound
US7335648B2 (en) 2003-10-21 2008-02-26 Inspire Pharmaceuticals, Inc. Non-nucleotide composition and method for inhibiting platelet aggregation
WO2005087266A1 (en) 2004-03-05 2005-09-22 Vddi Pharmaceuticals Combination therapy for inhibition of platelet aggregation
JP2009504737A (ja) 2005-08-19 2009-02-05 イーライ リリー アンド カンパニー 脈管疾患の治療又は予防のためのｐａｒ−１／ｐａｒ−４阻害剤の使用
DE102006020386A1 (de) 2006-04-28 2007-10-31 Dade Behring Marburg Gmbh Verfahren zur Bestimmung der Thrombozytenfunktion unter Flussbedingungen
US8252878B2 (en) * 2006-07-14 2012-08-28 Biocompatibles Uk Limited Polymer
DE102006051625A1 (de) * 2006-11-02 2008-05-08 Bayer Materialscience Ag Kombinationstherapie substituierter Oxazolidinone
CN101743001B (zh) 2007-04-13 2013-02-06 千年药品公司 用起因子xa抑制剂作用的化合物的组合抗凝治疗
KR20160033792A (ko) * 2007-04-27 2016-03-28 사이덱스 파마슈티칼스, 인크. 클로피도그렐 및 설포알킬 에테르 사이클로덱스트린을 함유하는 제형 및 사용 방법
KR20100029746A (ko) 2007-05-02 2010-03-17 포톨라 파마슈티컬스, 인코포레이티드 직접 작용하는 가역적인 ｐ2ｙ12 억제제의 정맥내 및 경구 투여
AU2008261691A1 (en) * 2007-06-11 2008-12-18 Nanovasc, Inc. Stents
US20090043380A1 (en) * 2007-08-09 2009-02-12 Specialized Vascular Technologies, Inc. Coatings for promoting endothelization of medical devices
US8998978B2 (en) * 2007-09-28 2015-04-07 Abbott Cardiovascular Systems Inc. Stent formed from bioerodible metal-bioceramic composite
WO2009070624A1 (en) * 2007-11-27 2009-06-04 The Trustees Of The University Of Pennsylvania Vascular stent
CA2623449C (en) 2008-03-27 2010-11-02 Lance Baldo A novel use of bivalirudin in the treatment of acute coronary syndrome
US9427448B2 (en) * 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
WO2009140092A1 (en) 2008-05-13 2009-11-19 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US8759316B2 (en) 2008-05-13 2014-06-24 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US20130303477A1 (en) 2008-05-13 2013-11-14 The Medicines Company Maintenance of Platelet Inhibition During Antiplatelet Therapy
US20120141468A1 (en) 2008-05-13 2012-06-07 Lisa Ruderman Chen Maintenance of platelet inhibition during antiplatelet therapy
US8680052B1 (en) * 2013-03-09 2014-03-25 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
KR101138294B1 (ko) * 2008-09-24 2012-04-25 김형일 혈관벽 임시 골격용 생분해성 블랜드
WO2011041217A1 (en) * 2009-10-02 2011-04-07 Schering Corporation The use of a par-1 antagonist in combination with a p2y12adp receptor antagonist for inhibition of thrombosis
US10376532B2 (en) * 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
CA2778880C (en) 2009-11-11 2018-02-13 The Medicines Company Methods of treating or preventing stent thrombosis
WO2011134478A2 (en) 2010-04-29 2011-11-03 Thrombologic Aps Methods of treatment of patients at increased risk of development of ischemic events and compounds hereof
CN103860459A (zh) 2012-12-11 2014-06-18 天津市汉康医药生物技术有限公司 一种坎格雷洛注射剂及其制备方法
BR112019022676A2 (pt) * 2017-06-23 2020-05-19 Chiesi Farm Spa método de prevenção de trombose de derivação da artéria sistêmica-para-pulmonar

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2733409C2 (ru) * 2015-01-14 2020-10-01 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Фармацевтические составы, включающие кангрелор высокой чистоты, и способы их получения и применения

Also Published As

Publication number Publication date
EP2498731A4 (en) 2015-02-25
BR112012011298A2 (pt) 2019-09-24
US20190167796A1 (en) 2019-06-06
WO2011060066A2 (en) 2011-05-19
US11147879B2 (en) 2021-10-19
BR112012011298B1 (pt) 2021-12-14
EP2498731A2 (en) 2012-09-19
EA028885B1 (ru) 2018-01-31
HRP20200445T1 (hr) 2020-06-12
DK2498731T3 (da) 2020-03-02
CA2778880C (en) 2018-02-13
CA2778880A1 (en) 2011-05-19
SI2498731T1 (sl) 2020-05-29
US20220008540A1 (en) 2022-01-13
PL2498731T3 (pl) 2020-07-13
WO2011060066A9 (en) 2011-08-25
AU2010319612A1 (en) 2012-05-24
AU2010319612B2 (en) 2016-01-14
EP2498731B1 (en) 2020-01-22
PT2498731T (pt) 2020-02-21
US9925265B2 (en) 2018-03-27
ES2773040T3 (es) 2020-07-09
US20110112030A1 (en) 2011-05-12

Similar Documents

Publication Publication Date Title
EA201270617A2 (ru) Способы лечения или предотвращения тромбоза стента
MX363243B (es) Composiciones para tratar cáncer y usos de dichas composiciones.
CY1116424T1 (el) Παραγωγο αδενινης ως αναστολεας ρι3κ
NI201000105A (es) Régimen de dosificación asociado con ésteres de paliperidona inyectables de acción prolongada.
EA201390060A1 (ru) Аннелированные пиримидины и триазины и их применение для лечения и/или профилактики сердечно-сосудистых заболеваний
EP2493464A4 (en) METHYLSULFONYLMETHANE (MSM) FOR THE TREATMENT OF DRUG-RESISTANT MICROORGANISMS
EA201590693A1 (ru) Ингибиторы gdf-8
EA201590165A1 (ru) Сдерживающие злоупотребление фармацевтические композиции для контролируемого высвобождения
EA201290583A1 (ru) Противовирусная терапия
EA201290859A1 (ru) Лечение люпус-артрита с использованием лаквинимода
EA201490254A1 (ru) Комбинированное лечение гепатита с
MX2017004618A (es) Inhibidores de la biosintesis de sulfato de heparano para el tratamiento de enfermedades.
HN2012000023A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
EA201200570A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201490721A1 (ru) Лекарственное средство для лечения заболеваний передней камеры глаза, включающее ребамипид и агент, удерживающий слезы
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
EA201190337A1 (ru) Способ лечения
PH12014502623B1 (en) Difluoro-hexahydro-cyclopentaoxazinyls and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors
EA201200428A1 (ru) Композиция и способ для лечения ожирения
MX2013008074A (es) Combinacion.
EA201490516A1 (ru) Бифенилкарбоксиамиды в качестве ингибиторов rock-киназ
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
PH12019501642A1 (en) Novel compounds and their use in the treatment of schistosomiasis
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
EA202090416A1 (ru) Способы лечения симптомов гастропареза с использованием велусетрага

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KG MD TJ TM